'There is no capital overhang,' according to Urs Wietlisbach at Partners Group, speaking at the EVCA Investors' Forum in Geneva on Wednesday. As Thomson revealed that nearly EUR 90bn was raised for investment last year, panelists were quick to point out that the rate of drawdown for LP commitments has increased by around 50% - an indication that the capital raised is indeed being put to work more quickly. This, however, means that LPs have to make investment decisions more quickly and with less information than they were once used to as funds return to market more quickly than ever.
Also backing the biotech startup were the Zürcher Kantonalbank and Greencross Medical Science Corp
Company plans to use the fresh capital to further expand, develop new features and scale up its team
EVentures, 468 Capital and HV Holtzbrinck back the round for the climate change mitigation app
Clessidra has been in negotiations for the acquisition of the Italian wine producer since February 2020